- Home
- >
- Torrance Clinic
- >
- Torrance Research Projects
Torrance Clinic
Research Projects
Bupropion for the Treatment of Methamphetamine Dependence: Phase 2/Double Blind
| Principal Investigator: | Nishant Kumar, D.O. |
| Research Coordinator: | Elena Nieves |
| Funded by: | National Institute on Drug Abuse |
| Grant Number: | R01 DA019063-01 |
| Total Project Period: | 2009-2011 |
Methamphetamine has become a major drug of abuse in this country for nearly a decade. As a result, the development of effective treatments for methamphetamine dependence has become a pressing concern for the national and global drug abuse treatment community. This project tests whether the drug, Bupropion, taken orally, is useful and safe for treating methamphetamine addiction. Two hundred ten (210) men and women at 12 research sites across the United States will participate in this study.
Titan Pharma. A Multi-Center Study of Probuphine in Patients with Opioid Dependence: A Randomized Placebo and Active-Controlled Study.
| Principal Investigator: | Nishant Kumar, D.O. |
| Research Coordinator: | Elena Nieves |
| Funded by: | Titan Pharmaceuticals, Inc. |
| Total Project Period: | 2010-2012 |
The use of buprenorphine (BPN) for the treatment of opioid dependence is now well-established and is gaining increased acceptance as a safe and useful office-based treatment for opioid dependence. Probuphine, an implantable formulation of buprenorphine hydrochloride (HCl) has been shown to be safe and well tolerated for Opioid addiction in previous trials. This clinical trial will further test the safety and efficacy of this medication. Up to 250 participants will be enrolled in this study.
Source: PRO-806 Clinical study protocol, 2009.
Titan Pharma. Titan Pharma. A Phase 3, Six Month, Open-Label Re-Treatment Study of Probuphine in Opioid Addiction.
| Principal Investigator: | Nishant Kumar, D.O. |
| Research Coordinator: | Elena Nieves |
| Funded by: | Titan Pharmaceuticals, Inc. |
| Total Project Period: | 2011-2012 |
The use of buprenorphine (BPN) for the treatment of opioid dependence is now well-established and is gaining increased acceptance as a safe and useful office-based treatment for opioid dependence. Probuphine, an implantable formulation of buprenorphine hydrochloride (HCl) has been shown to be safe and well tolerated for Opioid addiction in previous trials. This clinical trial, a continuation of PRO-806, will evaluate the safety of Probuphine in subjects who have completed 24 weeks of treatment and who will be re-treated with Probuphine over an additional 24 weeks. Up to 120 participants will be enrolled in this study.
Source: PRO-811 Clinical study protocol, 2010.
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
| Principal Investigator: | Nishant Kumar, D.O. |
| Research Coordinator: | Elena Nieves |
| Funded by: | Catalyst Pharmaceutical Partners/National Institute on Drug Abuse/Veterans Administration |
| Total Project Period: | 2011-2012 |
Cocaine addiction, a serious public health concern associated with significant medical, social, and economic consequences, is difficult to treat using traditional psychosocial and behavioral therapies. Despite testing of a number of different agents for cocaine dependency, there is no approved pharmacologic treatment for cocaine addiction. This project tests whether the drug, Vigabatrin, taken orally, is useful and safe for treating cocaine dependence. The study will be conducted at up 12 sites in the United States and involve approximately 200 subjects.